Solomon, D. H., Demler, O., Rist, P. M., Santacroce, L., Tawakol, A., Giles, J. T., Liao, K. P., & Bathon, J. M. (2024). Biomarkers of Cardiovascular Risk in Patients With Rheumatoid Arthritis: Results From the TARGET Trial. Journal of the American Heart Association, 13(5). https://doi.org/10.1161/jaha.123.032095

Zureigat, H., Civieri, G., Abohashem, S., Osborne, M. T., Solomon, D. H., Giles, J. T., Bathon, J., Massarotti, E., Unizony, S., & Tawakol, A. (2024). Improvement in joint inflammation is accompanied by reduction in arterial inflammation: Tocilizumab in rheumatoid arthritis. Journal of Nuclear Cardiology, 33, 101813. https://doi.org/10.1016/j.nuclcard.2024.101813

Solomon, D. H., Giles, J. T., Liao, K. P., Ridker, P. M., Rist, P. M., Glynn, R. J., Broderick, R., Lu, F., Murray, M. T., Vanni, K., Santacroce, L. M., Abohashem, S., Robson, P. M., Fayad, Z., Mani, V., Tawakol, A., & Bathon, J. (2022). Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 82(3), 324–330. https://doi.org/10.1136/ard-2022-223302

Ugarte-Gil, M. F., Hanly, J., Urowitz, M., Gordon, C., Bae, S.-C., Romero-Diaz, J., Sanchez-Guerrero, J., Bernatsky, S., Clarke, A. E., Wallace, D. J., Isenberg, D. A., Rahman, A., Merrill, J. T., Fortin, P. R., Gladman, D. D., Bruce, I. N., Petri, M., Ginzler, E. M., Dooley, M. A., … Alarcón, G. S. (2022). Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Annals of the Rheumatic Diseases, 81(11), 1541–1548. https://doi.org/10.1136/ard-2022-222487

Tang, W., Inzerillo, S., Weiner, J., Khalili, L., Barasch, J., Gartshteyn, Y., Dall’Era, M., Aranow, C., Mackay, M., & Askanase, A. (2022). The Impact of Telemedicine on Rheumatology Care. Frontiers in Medicine, 9. https://doi.org/10.3389/fmed.2022.876835

Wang, R., Dasgupta, A., & Ward, M. M. (2022). Predicting Probability of Response to Tumor Necrosis Factor Inhibitors for Individual Patients With Ankylosing Spondylitis. JAMA Network Open, 5(3), e222312. https://doi.org/10.1001/jamanetworkopen.2022.2312